Study shows no safety concerns for Gaucher's switch

Protalix Biotherapeutics Inc. (NYSE-A:PLX; Tel Aviv:PLX) said preliminary data from the first 15 Gaucher's disease patients in a Phase III trial showed that switching from Cerezyme imiglucerase to an ...